絞り込み

16737

広告

「こころを読む」能力を初めてサルから特定 自閉症治療法確立に貢献 新潟大など (財経新聞)

厚生労働省によると自閉症の症状をもつ人の割合は、約100人に1人いるといわれている。だが自閉症の背後にある脳のメカニズムについて謎が多いという。新潟大学は1日、...

  1. [企業] CAR-Tを開発するGilea...
  2. 「医療機関向け情報(治療ガイドライン、臨...
  3. チタンを用いた生体軟組織用の強力瞬間接着...
  4. [企業] AstraZenecaからRe...

ニュース一覧

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone.

著者 Schoretsanitis G , Spina E , Hiemke C , de Leon J
Expert Rev Clin Pharmacol.2017 Jul 12 ; ():1-17.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Miscellaneous

Other Literature Sources

This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value around 7 in oral risperidone). The weighted mean R/9-OH-R ratio was 0.48 (approximately twice that of oral risperidone TDM) in a combined analysis from 329 patients in 6 risperidone LAI studies without major confounders. The total C/D ratios from 297 patients in 6 risperidone LAI studies ranged from 7.4 to 9.7 ng/ml/mg/day with a weighted mean of 8.8 ng/ml/mg/day. Expert commentary: Clinicians using TDM for risperidone LAI microsphere formulation need to: 1) consider steady state to be reached ≥ 6 weeks after the first injection, 2) pay attention to a) co-medications with inducers/inhibitors, b) severe inflammations/infections, and c) hepatic/renal impairment, and 3) use Castberg's recommendation to calculate risperidone dosing.
PMID: 28699847 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード